MARKET

KYTX

KYTX

Kyverna Therapeutics
NASDAQ
7.80
-0.04
-0.51%
After Hours: 7.80 0 0.00% 17:55 12/05 EST
OPEN
7.96
PREV CLOSE
7.84
HIGH
8.08
LOW
7.77
VOLUME
268.31K
TURNOVER
--
52 WEEK HIGH
8.45
52 WEEK LOW
1.780
MARKET CAP
341.61M
P/E (TTM)
-2.0963
1D
5D
1M
3M
1Y
5Y
1D
Kyverna Therapeutics Is Maintained at Overweight by Morgan Stanley
Dow Jones · 1d ago
Morgan Stanley Maintains Overweight on Kyverna Therapeutics, Raises Price Target to $25
Benzinga · 1d ago
Donaldson Posts Upbeat Results, Joins Science Applications International, Descartes Systems, Dollar General And Other Big Stocks Moving Higher On Thursday
Benzinga · 1d ago
Morgan Stanley Remains a Buy on Kyverna Therapeutics, Inc. (KYTX)
TipRanks · 1d ago
Kyverna Therapeutics price target raised to $25 from $20 at Morgan Stanley
TipRanks · 1d ago
Weekly Report: what happened at KYTX last week (1124-1128)?
Weekly Report · 5d ago
Kyverna Therapeutics, Inc.: A Promising Market Position with KYV-101’s Potential as the First FDA-Approved CAR-T Therapy for Autoimmune Diseases
TipRanks · 11/24 11:27
Weekly Report: what happened at KYTX last week (1117-1121)?
Weekly Report · 11/24 09:48
More
About KYTX
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. The Company’s lead chimeric antigen receptor (CAR) T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase II trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase I/II trials for patients with lupus nephritis. KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate incorporating highly potent CD28 co-stimulation. The Company is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Its pipeline includes next generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.

Webull offers Kyverna Therapeutics Inc stock information, including NASDAQ: KYTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KYTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KYTX stock methods without spending real money on the virtual paper trading platform.